Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.
As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.
Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).
Direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT), shows research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati.